CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 420 filers reported holding CRISPR THERAPEUTICS AG in Q2 2023. The put-call ratio across all filers is 0.90 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $254,213 | -23.9% | 5,620 | -31.6% | 0.14% | -29.4% |
| Q4 2022 | $334,074 | -60.3% | 8,218 | -36.2% | 0.19% | -62.6% |
| Q3 2022 | $842,000 | -69.2% | 12,878 | -71.4% | 0.52% | -68.4% |
| Q2 2022 | $2,737,000 | -45.6% | 45,036 | -43.8% | 1.64% | -32.6% |
| Q1 2022 | $5,027,000 | +29.7% | 80,082 | +27.9% | 2.44% | +18.6% |
| Q4 2021 | $3,876,000 | -42.8% | 62,609 | +3.5% | 2.06% | -28.8% |
| Q3 2021 | $6,772,000 | +4.9% | 60,499 | +51.7% | 2.89% | -8.3% |
| Q2 2021 | $6,458,000 | +39.9% | 39,891 | +5.3% | 3.15% | +26.2% |
| Q1 2021 | $4,617,000 | -29.1% | 37,892 | +13.2% | 2.50% | -26.4% |
| Q4 2020 | $6,509,000 | – | 33,480 | – | 3.39% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |